左乙拉西坦与苯妥英用于无癫痫病史患者开颅术后癫痫预防的比较:系统评价与Meta分析
该系统评价与Meta分析纳入7项研究共803例无癫痫病史的开颅术后成人患者,比较左乙拉西坦与苯妥英预防开颅术后新发癫痫的疗效与耐受性。左乙拉西坦组癫痫发生率1.26%(4/318)低于苯妥英组6.60%(32/485),Peto OR 0.233(95%CI 0.117-0.462,p<0.001)。两组不良反应总发生率无统计学显著差异(p=0.44),但苯妥英组因不良反应停药率更高(POR 0.266,95%CI 0.137-0.518,p<0.001)。
要点
- 左乙拉西坦预防开颅术后癫痫优于苯妥英(POR 0.233,95%CI 0.117-0.462,p<0.001)。
- 左乙拉西坦组癫痫发生率1.26%(4/318),苯妥英组6.60%(32/485)。
- 两组不良反应总发生率无统计学显著差异(p=0.44),苯妥英组因不良反应停药更多。
核心结论
- 对于非创伤性病变开颅术后患者,左乙拉西坦预防开颅术后癫痫优于苯妥英,且导致停药的严重不良反应更少。
- 作者认为需要进一步开展高质量研究比较左乙拉西坦与安慰剂,为制定抗癫痫药物指南提供证据。
研究设计与样本
- 系统评价与Meta分析,检索PubMed、Embase、Web of Science和Cochrane Library中比较左乙拉西坦与苯妥英预防开颅术后癫痫的研究。
- 纳入标准为无癫痫病史的成人开颅术后患者,预防性使用苯妥英,对照组以左乙拉西坦治疗为主要组间差异,且可获得各组患者数和癫痫发作数数据。
- 排除脑损伤及既往有癫痫发作史的患者,共纳入7项研究803例患者。
- 癫痫发生率采用Peto比值比(POR)计算,为罕见事件二分类数据的相对效应估计方法。
主要发现
- 左乙拉西坦组开颅术后癫痫发生率为1.26%(4/318),苯妥英组为6.60%(32/485)。
- Meta分析显示左乙拉西坦预防开颅术后癫痫显著优于苯妥英(POR 0.233,95%CI 0.117-0.462,p<0.001)。
- 亚组分析显示,所有脑疾病所致开颅术后癫痫中左乙拉西坦优于苯妥英(POR 0.129,95%CI 0.039-0.423,p=0.001),肿瘤亚组亦优于苯妥英(POR 0.282,95%CI 0.117-0.678,p=0.005)。
- 左乙拉西坦组不良反应包括认知障碍、血栓性静脉炎、易激惹、嗜睡、疲倦和乏力;苯妥英组皮疹、过敏反应、心律失常和低钠血症更常见。
- 苯妥英组不良反应总发生34/466,左乙拉西坦组26/432,两组无统计学显著差异(p=0.44);因不良反应停用抗癫痫药物者苯妥英组53/297,左乙拉西坦组6/196(POR 0.266,95%CI 0.137-0.518,p<0.001)。
关键数值与推荐
- 开颅术后癫痫发生率:左乙拉西坦组1.26%(4/318) vs 苯妥英组6.60%(32/485),POR 0.233(95%CI 0.117-0.462,p<0.001)。
- 所有脑疾病亚组POR 0.129(95%CI 0.039-0.423,p=0.001);肿瘤亚组POR 0.282(95%CI 0.117-0.678,p=0.005)。
- 不良反应总发生率:苯妥英组34/466 vs 左乙拉西坦组26/432,p=0.44,无统计学显著差异。
- 因不良反应停药率:苯妥英组53/297 vs 左乙拉西坦组6/196,POR 0.266(95%CI 0.137-0.518,p<0.001)。
临床怎么用
- 对于无癫痫病史的非创伤性病变开颅术后成人患者,左乙拉西坦在预防开颅术后癫痫方面优于苯妥英,且导致停药的严重不良反应更少。
- 作者认为需要进一步开展高质量研究比较左乙拉西坦与安慰剂,为制定抗癫痫药物指南提供证据。
局限性
- 作者认为需要进一步开展高质量研究比较左乙拉西坦与安慰剂,为制定抗癫痫药物指南提供证据。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVEDe novo seizure following craniotomy (DSC) for nontraumatic pathology may adversely affect medical and neurological outcomes in patients with no history of seizures who have undergone craniotomies. Antiepileptic drugs (AEDs) are commonly used prophylactically in patients undergoing craniotomy; however, evidence supporting this practice is limited and mixed. The authors aimed to collate the available evidence on the efficacy and tolerability of levetiracetam monotherapy and compare it with that of the classic AED, phenytoin, for DSC.METHODSPubMed, Embase, Web of Science, and the Cochrane Library were searched for studies that compared levetiracetam with phenytoin for DSC prevention. Inclusion criteria were adult patients with no history of epilepsy who underwent craniotomy with prophylactic usage of phenytoin, a comparator group with levetiracetam treatment as the main treatment difference between the two groups, and availability of data on the numbers of patients and seizures for each group. Patients with brain injury and previous seizure history were excluded. DSC occurrence and adverse drug reaction (ADR) were evaluated. Seizure occurrence was calculated using the Peto odds ratio (POR), which is the relative effect estimation method of choice for binary data with rare events.RESULTSData from 7 studies involving 803 patients were included. The DSC occurrence rate was 1.26% (4/318) in the levetiracetam cohort and 6.60% (32/485) in the phenytoin cohort. Meta-analysis showed that levetiracetam is significantly superior to phenytoin for DSC prevention (POR 0.233, 95% confidence interval [CI] 0.117-0.462, p < 0.001). Subgroup analysis demonstrated that levetiracetam is superior to phenytoin for DSC due to all brain diseases (POR 0.129, 95% CI 0.039-0.423, p = 0.001) and tumor (POR 0.282, 95% CI 0.117-0.678, p = 0.005). ADRs in the levetiracetam group were cognitive disturbance, thrombophlebitis, irritability, lethargy, tiredness, and asthenia, whereas rash, anaphylaxis, arrhythmia, and hyponatremia were more common in the phenytoin group. The overall occurrence of ADR in the phenytoin (34/466) and levetiracetam (26/432) groups (p = 0.44) demonstrated no statistically significant difference in ADR occurrence. However, the discontinuation rate of AEDs due to ADR was 53/297 in the phenytoin group and 6/196 in the levetiracetam group (POR 0.266, 95% CI 0.137-0.518, p < 0.001).CONCLUSIONSLevetiracetam is superior to phenytoin for DSC prevention for nontraumatic pathology and has fewer serious ADRs that lead to discontinuation. Further high-quality studies that compare levetiracetam with placebo are necessary to provide evidence for establishing AED guidelines.
引用
- Lee CH, Koo HW, Han SR, et al. Phenytoin versus levetiracetam as prophylaxis for postcraniotomy seizure in patients with no history of seizures: systematic review and meta-analysis. J Neurosurg. 2018. PMID: 30004278. doi:10.3171/2018.4.JNS1891
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。